Study Finds that Telemedicine Visits Cost Far Less than Office Visits

Why It Matters

The findings demonstrate that telemedicine can substantially lower health‑system expenses while maintaining care continuity, offering a financial buffer for hospitals facing tightening margins. Sustaining supportive policy is crucial to preserve these savings.

Key Takeaways

• Telemedicine episodes cost $96, in‑person $509
• Average savings $400 per visit, five‑fold cheaper
• Follow‑up visits drop from >4 to ~3 per episode
• Study covers 160,000 visits across five UPHS hospitals
• Potential savings risk lapsing if regulations revert

Pulse Analysis

Telemedicine’s rapid expansion during the COVID‑19 pandemic has evolved into a permanent fixture of modern health‑care delivery. The University of Pennsylvania study, which examined 160,000 encounters across five hospitals, quantifies that shift: an average episode charge of $96 for virtual visits versus $509 for traditional office appointments. This five‑fold cost differential stems from reduced facility overhead, streamlined staffing, and the elimination of ancillary services that are often unnecessary for routine conditions such as respiratory infections.

Beyond headline savings, the data reveal operational efficiencies that resonate with health‑system executives. Patients initiating care via telemedicine required roughly three follow‑up encounters, compared with more than four for in‑person starters, indicating that virtual triage can resolve many issues without additional resource consumption. The effect is especially pronounced for low‑complexity ailments, where virtual assessments avoid costly imaging or lab work, while mental‑health visits show comparable episode charges but still benefit from fewer subsequent appointments. These dynamics enable hospitals to reallocate funds toward high‑margin services, technology upgrades, and community outreach.

However, the financial upside hinges on a regulatory environment that continues to support remote care. Current policies, many of which were temporary extensions granted during the pandemic, are set to expire in 2027. If reimbursement rates revert to pre‑COVID levels or geographic restrictions tighten, the cost advantage could diminish, threatening the sustainability of telemedicine‑driven savings. Stakeholders therefore must advocate for permanent, value‑based reimbursement models and invest in interoperable telehealth platforms to lock in the efficiencies demonstrated by the study.